fda approves first oral glp-1 obesity drug august 1 2025 Wegovy Pill Wins Approval as Treatment for and Weight Loss Novo Nordisk's weight-loss pill wins

His work focuses on how microbial ecosystems interact with human physiology, including: Gut barrier function and intestinal permeability Mucus-associated microbiota (Akkermansia-related systems) Oralgut microbiome axis Short-chain fatty acids (SCFAs) and metabolic signaling Circadian rhythmmicrobiome interactions Clinical Research Contributions He has contributed to multiple clinical-stage microbiome programs, supporting bacterial strain discovery, optimization, and formulation design across different therapeutic areas, including: Active Ulcerative Colitis (Inflammatory Bowel Disease) Hyperoxaluria (Oxalate Metabolism Disorder) Microbiome-driven gut health and inflammatory conditions These studies were part of broader clinical development programs evaluating microbiome-based approaches

GLP-1 controls specific types of appetite rather than baseline hunger

Diab Vasc Dis Res

Weight loss effects of GLP-1RAs Liraglutide (3.0 mg, Saxenda), a GLP-1RA that activates the GLP-1 receptor, was approved by the FDA in December 2014 for adult obesity treatment [38] and has recently shown efficacy in adolescents aged 12 to 18 years

The anti-inflammatory effects are often considered key mechanisms through which Ex-4 exerts its tumor-suppressive functions [96]

This widespread distribution means GLP-1 affects multiple systems simultaneously